Emerging BCMA-directed CAR T-Cell Therapies in RRMM

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.

In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.

The phase 3 DREAMM-7 trial met its primary end point of progression-free survival, and overall survival data is trending positively.

Steady-state and chemotherapy-based mobilization both demonstrate feasibility in stem cell collection for patients with multiple myeloma undergoing autologous stem cell transplants, but challenges remain.

In the first article of a 2-part series, Sumit Madan, MD, discusses how the combination of selinexor, bortezomib, and dexamethasone shows superior survival outcomes for patients with relapsed/refractory multiple myeloma that are proteasome inhibitor naive or have high-risk cytogenetics.